Results 71 to 80 of about 15,210 (229)

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma [PDF]

, 2016
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes.
Azab, M., Cannito, S., CAPPELLO, Francesco, Jueliger, S., Lo Re, O., Lyons, J., Pata, I., Pata, P., Pazienza, V., Peyrou, M., RAPPA, Francesca, Shkolnaya, M., Taverna, P., Villarroya, F., Vinciguerra, M.   +14 more
core   +2 more sources

Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom

British Journal of Haematology, EarlyView.
Summary This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.
Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group   +35 more
wiley   +1 more source

Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection

Nature Communications, 2019
The development of post-chemotherapy resistance is a significant issue in the management of AML. Here, Caiado et al. suggest that the issue might be circumvented via upfront combination with hypomethylating agents that shape the clonal dynamics and ...
Francisco Caiado, Diogo Maia-Silva, Carolina Jardim, Nina Schmolka, Tânia Carvalho, Cláudia Reforço, Rita Faria, Branka Kolundzija, André E. Simões, Tuncay Baubec, Christopher R. Vakoc, Maria Gomes da Silva, Markus G. Manz, Ton N. Schumacher, Håkan Norell, Bruno Silva-Santos   +15 more
doaj   +1 more source

RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway

Cell Death and Disease
Myelodysplastic syndromes (MDS) are clonal hematopoietic malignancies and seriously threaten people’s health. Current therapies include bone marrow transplantation and several hypomethylating agents.
Li Liu, Chaoying Yang, Lin Zhu, Yanyan Wang, Fuxiang Zheng, Long Liang, Pengfei Cao, Jing Liu, Xu Han, Ji Zhang   +9 more
doaj   +1 more source

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Nature Communications, 2019
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a ...
Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl   +23 more
doaj   +1 more source

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)

Case Reports in Hematology, 2020
T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS) is an uncommon and aggressive leukemia without well-established treatment guidelines, particularly when relapsed.
Heather Klocke, Zhao Ming Dong, Craig O’Brien, Nicholas Burwick, Robert E. Richard, Daniel Y. Wu, Thomas R. Chauncey, Solomon A. Graf   +7 more
doaj   +1 more source

An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

Cancer Science, EarlyView.
An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.
Yu‐Hung Wang, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Luca Guarnera, Wan‐Hsuan Lee, Chi‐Yuan Yao, Andres Jerez, Kristian Gurashi, Kiran Batta, Hsin‐An Hou, Wen‐Chien Chou, Mrinal S. Patnaik, Jaroslaw Maciejewski, Daniel H. Wiseman, Chien‐Chin Lin, Hwei‐Fang Tien   +16 more
wiley   +1 more source

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Journal of Hematology & Oncology, 2012
Background Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation ...
Fianchi Luana, Criscuolo Marianna, Lunghi Monia, Gaidano Gianluca, Breccia Massimo, Levis Alessandro, Finelli Carlo, Santini Valeria, Musto Pellegrino, Oliva Esther N, Leoni Pietro, Spiriti Antonietta, D’Alò Francesco, Hohaus Stefan, Pagano Livio, Leone Giuseppe, Voso Maria   +16 more
doaj   +1 more source

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

Chinese Medical Journal, 2020
. Epigenetic regulation includes changes of DNA methylation and modifications of histone proteins and is essential for normal physiologic functions, especially for controlling gene expression.
Qing-Yu Xu, Li Yu, Peng Lyu
doaj   +1 more source

IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells [PDF]

, 2018
In high-grade serous ovarian cancer (OC), chemotherapy eliminates the majority of tumor cells, leaving behind residual tumors enriched in OC stem cells (OCSC).
Berek, Canino, Fang, Han, Kastan, Paschall, Pasquier, Wang, Wang, Zou, Ørskov   +10 more
core   +1 more source